– Gilde has invested in Pharmaline, based in Oldenzaal the Netherlands. Pharmaline is specialized in large scale pharmaceutical compounding. The company is one of the few Dutch players whose facilities and production processes are structured to comply with the guidelines of the Dutch…
– Moximed, Inc. announced today that the KineSpring® System, an implantable medical spring that works by unloading the weight on the diseased knee joint, has been successfully implanted in the first patient enrolled in its US clinical study, SOAR. This prospective, single-arm clinical…
– Prosonix (Oxford, UK), a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its unique particle engineering technology, announces the election of Dr Ken Cunningham as Non-executive Chairman. He replaces Dr Jim Philips, who has been…
– Gene expression profile could have utility to predict responses to targeted therapies and chemotherapies in multiple cancer types IRVINE, CA and AMSTERDAM, THE NETHERLANDS - Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced…
– Munich, Germany – Definiens AG, the leader in image analysis for Digital Pathology, today announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman. Following the recent financing round led by Gilde Healthcare…
– Freising, Germany – Pieris AG announced today the achievement of the first financial milestone in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568). The milestone recognizes the…
– Clinical Data with the KineSpring® System Released KineSpring System Highlighted at the London Knee Meeting HAYWARD, Calif. & LONDON - KineSpring System Highlighted at the London Knee Meeting. For the millions of patients with mild to moderate knee osteoarthritis (wear), an innovative…
– 60% of patients in DAS28 remission at week 12 ACR20 score of 80% at week 12 Very encouraging safety profile at all administered doses Rapid onset of activity with some patients achieving remission as early as week 2 GHENT, Belgium — Ablynx [Euronext Brussels: ABLX] today announced…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced a collaboration with Merck & Co., Inc., through a subsidiary, to develop and commercialise Nanobody® candidates directed towards a voltage gated ion channel with the option to develop and commercialise a Nanobody to…
– Munich, Germany – Definiens AG, the leader in Image Analysis for Digital Pathology, today announced that it has closed a private round of financing of €10 million. The financing was led by Gilde Healthcare Partners. Existing investors including TVM, Cipio and Definiens’ management…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa proof-of-concept study investigating APD403 for the prevention of acute nausea & vomiting in cancer patients receiving…
– Arnhem/Elden – Villa Oosterveld met 18 kamers is 21 september officieel geopend door de wethouder van Zorg en Welzijn Henk Kok. Villa Oosterveld is weer open. Het voormalige klooster is nu een Stepping Stones Home & Care zorgvilla voor hulpbehoevende en dementerende ouderen die niet…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that they have advanced the Nanobody® candidate ALX-0751, together with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, into pre-clinical development in the field of oncology. This is the second pre-clinical…
– SILVER SPRING, Md. - United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has signed an exclusive agreement with Ascendis Pharma A/S to apply Ascendis Pharma's proprietary TransCon technology platform to United Therapeutics' treprostinil molecule, the active ingredient…
– ALX-0171 has the potential to become a first-in-class therapy GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically…
– BEDFORD, Mass – iWalk Inc., the leader in Personal Bionics, announced that it has closed a private equity financing round of $17 million led by Gilde Healthcare Partners. Existing investors, including WFD Ventures, General Catalyst Partners, and Sigma Partners also participated in…
– COPENHAGEN, DENMARK – Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting…
– Utrecht, The Netherlands – uniQure (Amsterdam, the Netherlands) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) that recommends marketing authorization of Glybera® (alipogene tiparvovec) as a treatment for…
– SAN DIEGO, CA and EDMONTON, CANADA — Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor. The objective of…
– Additional Phase II data (ACR20 84%; DAS28 remission 38%) demonstrates that ozoralizumab could have an important competitive and differentiated position in the $24 billion TNFa market Data from the open-label study suggest that ozoralizumab enables individualised treatment, a real…
– Leiden, The Netherlands & Seattle – ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery. FINISH-3…
– Amsterdam, The Netherlands and Irvine, CA – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that the company has raised USD $65 million in a private round of equity financing. The financing round was led by the Debiopharm…
– Cambridge, UK – Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study showed that APD421 significantly reduced the incidence of nausea and vomiting compared to placebo in adult surgical patients…
– Doorn — De reeds 45 jaar bestaande zorgvilla Nimmerdor Staete op de Julianaweg 47 in Doorn is overgenomen door Stepping Stones Home & Care, bekend in de regio van o.a. Poort van Wijk op de grens tussen Cothen en Wijk bij Duurstede. Niet alleen de eigenaar is veranderd, maar ook de…
– — Results Support Differentiating Drug-like Features for Targeted Anti-cancer Drug — Chicago, Illinois — Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company’s proprietary c-Met antagonist program, PRS-110, at the American…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration…
– LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis, announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically significant…
– IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, an innovative molecular cancer diagnostics company, today announced that the company has signed a contract with Blue Shield of California, making Agendia an in-network provider. The move paves the way for future in-network coverage…
– LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces the initiation of a Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant…